Alterations of DNA damage response pathway:Biomarker and therapeutic strategy for cancer immunotherapy

被引:12
|
作者
Minlin Jiang [1 ,2 ]
Keyi Jia [1 ,2 ]
Lei Wang [1 ]
Wei Li [1 ]
Bin Chen [1 ]
Yu Liu [1 ,2 ]
Hao Wang [1 ,2 ]
Sha Zhao [1 ]
Yayi He [1 ]
Caicun Zhou [1 ]
机构
[1] Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine
[2] Medical School, Tongji University
基金
中国国家自然科学基金;
关键词
D O I
暂无
中图分类号
R730.51 [免疫疗法];
学科分类号
100214 ;
摘要
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response(DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1(PD-L1) and interact with signaling such as cyclic GMPe AMP synthase-stimulator of interferon genes(cGASe STING) signaling. Here, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR alterations on immune system, and the potential applications of DDR alterations as biomarkers and therapeutic targets in cancer immunotherapy.
引用
收藏
页码:2983 / 2994
页数:12
相关论文
共 50 条
  • [1] Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
    Jiang, Minlin
    Jia, Keyi
    Wang, Lei
    Li, Wei
    Chen, Bin
    Liu, Yu
    Wang, Hao
    Zhao, Sha
    He, Yayi
    Zhou, Caicun
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 2983 - 2994
  • [2] mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy
    Pazhooh, Romina Danesh
    Farnood, Parnia Rahnamay
    Asemi, Zatollah
    Mirsafaei, Liaosadat
    Yousefi, Bahman
    Mirzaei, Hamed
    DNA REPAIR, 2021, 104
  • [3] Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
    Catalano, Fabio
    Borea, Roberto
    Puglisi, Silvia
    Boutros, Andrea
    Gandini, Annalice
    Cremante, Malvina
    Martelli, Valentino
    Sciallero, Stefania
    Puccini, Alberto
    CANCERS, 2022, 14 (06)
  • [4] Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
    Huang, Tzu-Ting
    Lampert, Erika J.
    Coots, Cynthia
    Lee, Jung-Min
    CANCER TREATMENT REVIEWS, 2020, 86
  • [5] Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
    Flem-Karlsen, Karine
    McFadden, Erin
    Omar, Nasrin
    Haugen, Mads H.
    Oy, Geir Frode
    Ryder, Truls
    Gullestad, Hans Petter
    Hermann, Robert
    Maelandsmo, Gunhild Mari
    Florenes, Vivi Ann
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 895 - 905
  • [6] The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
    Mauri, G.
    Arena, S.
    Siena, S.
    Bardelli, A.
    Sartore-Bianchi, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1135 - 1147
  • [7] Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 997 - +
  • [8] Targeting the nucleolar DNA damage response as a therapeutic strategy in ovarian cancer
    Sanij, Elaine
    Xuan, Jiachen
    Brajanovski, Natalie
    Kwang, Diannita
    Chan, Keefe
    Beetham, Henry
    Simpson, Kaylene
    Mileshkin, Linda
    Scott, Clare
    Pearson, Richard B.
    CANCER SCIENCE, 2023, 114 : 189 - 189
  • [9] DNA repair pathway alterations and correlation with immunotherapy response.
    Hernandez-Guerrero, Tatiana
    Pedregal, Manuel
    Rubio, Jaime
    Ruiz-Hispan, Eva
    Fernandez, Marina
    Martinez, Lmanol
    Doger, Bernard
    Lage Alfranca, Yolanda
    Belen Ruperez, Ana
    Zenzola, Victor
    Casado, Victoria
    Ignacio Martin-Valades, Jose
    Carvajal, Nerea
    Chamizo, Cristina
    Domine, Manuel
    Garcia Foncillas, Jesus
    Moreno, Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
    Duttagupta, Sreya
    Hakozaki, Taiki
    Routy, Bertrand
    Messaoudene, Meriem
    CURRENT ONCOLOGY, 2023, 30 (11) : 9406 - 9427